<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://vitalspanwire.com/news/cytotoxic-cd4-t-cells-centenarians-longevity</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-20T11:02:23.337Z</news:publication_date><news:title>Rare cytotoxic T cells expand in centenarians, but their role in longevity remains unclear</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/intismeran-keytruda-phase-3-melanoma-endpoints</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-19T21:02:24.444Z</news:publication_date><news:title>Intismeran combination meets Phase 3 melanoma endpoints, but effect size remains undisclosed</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/diabetes-vision-loss-young-adults-global-burden</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-19T16:02:29.611Z</news:publication_date><news:title>Diabetes-related vision loss rose among young adults in global burden analysis</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/myth-diet-aging-mortality-observational-study</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-19T11:02:20.683Z</news:publication_date><news:title>Machine-derived diet score tracks lower aging-related mortality—but does not prove a longevity diet</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/efgartigimod-phase-3-autoimmune-myositis-alkivia</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-18T21:03:39.681Z</news:publication_date><news:title>Argenx reports Phase 3 efgartigimod benefit in autoimmune myositis</news:title></news:news></url><url><loc>https://vitalspanwire.com/news/fda-competency-reviews-generative-ai-medical-devices</loc><news:news><news:publication><news:name>Vitalspan Wire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-18T16:01:55.880Z</news:publication_date><news:title>FDA explores competency-based reviews for generative-AI medical devices</news:title></news:news></url></urlset>